首页> 外文OA文献 >The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population
【2h】

The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population

机译:体外高强度聚焦超声(HIFU)在西方人群中治疗肝肾肿瘤的安全性和可行性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

High-intensity focused ultrasound (HIFU) provides a potential noninvasive alternative to conventional therapies. We report our preliminary experience from clinical trials designed to evaluate the safety and feasibility of a novel, extracorporeal HIFU device for the treatment of liver and kidney tumours in a Western population. The extracorporeal, ultrasound-guided Model-JC Tumor Therapy System (HAIFU™ Technology Company, China) has been used to treat 30 patients according to four trial protocols. Patients with hepatic or renal tumours underwent a single therapeutic HIFU session under general anaesthesia. Magnetic resonance imaging 12 days after treatment provided assessment of response. The patients were subdivided into those followed up with further imaging alone or those undergoing surgical resection of their tumours, which enabled both radiological and histological assessment. HIFU exposure resulted in discrete zones of ablation in 25 of 27 evaluable patients (93%). Ablation of liver tumours was achieved more consistently than for kidney tumours (100 vs 67%, assessed radiologically). The adverse event profile was favourable when compared to more invasive techniques. HIFU treatment of liver and kidney tumours in a Western population is both safe and feasible. These findings have significant implications for future noninvasive image-guided tumour ablation.
机译:高强度聚焦超声(HIFU)为常规疗法提供了潜在的无创替代方法。我们从临床试验中报告我们的初步经验,这些临床试验旨在评估新型HIFU体外治疗西方人群肝肾肿瘤的安全性和可行性。超声引导下的体外JC型肿瘤治疗系统(HAIFU™技术公司,中国)已根据四个试验方案用于治疗30例患者。肝或肾肿瘤患者在全身麻醉下接受一次HIFU治疗。治疗后12天的磁共振成像可评估反应。将患者分为单独进行进一步影像学检查的患者或进行肿瘤手术切除的患者,这些患者可以进行放射学和组织学评估。 HIFU暴露导致27位可评估患者中的25位(93%)出现消融区。肝肿瘤的消融比肾脏肿瘤更一致(放射学评估为100比67%)。与更具侵入性的技术相比,不良事件的发生是有利的。 HIFU治疗西方人群的肝肾肿瘤既安全又可行。这些发现对未来无创图像引导的肿瘤消融具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号